4 Hematology Headlines You Missed In March 2026

In polycythemia vera (PV), the US Food and Drug Administration (FDA) has granted Priority Review to rusfertide, a first-in-class hepcidin mimetic targeting iron dysregulation, based on phase 3 VERIFY and supportive...